Is Teva A Falling Drug Company Or A Great Value Proposition (NYSE:TEVA) | Seeking Alpha
Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement | Barron's
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
Well, well,we'll...said he didn't know why “his team” invested which lowered the stock for months then just doubled his… | Dow jones companies, Investing, Dow jones
Teva's Stock Slides After U.S. Sues Over Copay Kickback Claims | Barron's
Teva Stock Pressured From Antitrust Lawsuit Against Drug Makers | Barron's
Drugmaker Teva Pharmaceuticals found guilty for contribution to opioid crisis - MarketWatch
Opinion: Multinationals learn the limits of being big - MarketWatch
Teva Stock Sees Another Big Buy From Chairman Sol Barer | Barron's
Teva shares surge on corporate shake-up - MarketWatch
Teva's Earnings and Outlook Miss Estimates. Currency Moves Are to Blame. | Barron's
Teva Appoints New Chief Executive After Months of Speculation - WSJ
Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva shares rise as company offers reassurance on former flagship drug Copaxone - MarketWatch
Teva releases generic version of Mylan's EpiPen in limited doses in the U.S. - MarketWatch
Perrigo rejects Mylan, opening door for Teva - MarketWatch
Teva Pharmaceutical Names Richard Francis as CEO, President - WSJ
What To Do After TEVA Stock Falls Below $10 Again (NYSE:TEVA) | Seeking Alpha
Opinion: Multinationals learn the limits of being big - MarketWatch
Teva's generic EpiPen approved in the U.S., with perfect timing - MarketWatch
MarketWatch on Twitter: "Teva Pharmaceutical named Kare Schultz as its new chief executive https://t.co/pyLR2vL5Ep https://t.co/pD8godrT5C" / Twitter
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva to lay off 14,000 workers in bid for survival — but some are skeptical - MarketWatch
Teva Pharmaceutical CEO Talks Opioids, Lawsuits, and the Long Road Ahead | Barron's
Teva Pharmaceutical Is in Recovery - WSJ
Mylan sees opportunity in rival Teva's weakness - MarketWatch
